The effects of glibenclamide on insulin requirements, Hb A 1c levels and lipid profiles of patients with type I diabetes mellitus

Abstract

This study was planned to evaluate the effects of glibenclamide, a second generation sulphonylurea drug, given in addition to insulin therapy, on blood glucose, Hb A 1c levels and lipid profiles of patients with type I diabetes mellitus. Two groups of patients with type I diabetes mellitus were included in the study. Ten patients in group I received insulin and diet therapy, 10 patients in group II received glibenclamide (5 mg) in addition to this therapy. Both groups were followed-up for 6 months and blood samples were collected at 3 months intervals. Blood glucose, Hb A 1c, HDL cholesterol, LDL cholesterol levels were determined at the beginning, at the 3rd and 6th months. Total cholesterol and triglyceride were determined at the beginning and at the 6th month. Blood glucose, Hb A 1c, HDL cholesterol, LDL cholesterol, total cholesterol, triglyceride levels and insulin requirements of group I did not differ significantly from the beginning at 3 and 6 months (p > 0.05). There was a significant decrease in the insulin requirements of patients in group II at the end of 3 months and blood glucose, Hb A 1c, total cholesterol and triglyceride levels decreased, HDL cholesterol and triglyceride levels decreased. HDL cholesterol levels increased significantly at the end of 6 months (p < 0.05).